Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas

Deepti Behl, Kay Ristow, Svetomir Nenad Markovic, Thomas Elmer Witzig, Thomas Matthew Habermann, Joseph P. Colgan, David J. Inwards, William L. White, Stephen Maxted Ansell, Ivana Micallef, Patrick Bruce Johnston, Luis F. Porrata

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The immunologic mechanisms of action of rituximab include complement mediated lysis and antibody-dependent cellular cytotoxicity. We hypothesised that a stronger host immune system prior to rituximab therapy for follicular (grades 1and 2) lymphomas (FL) would result in better response rates and longer time to progression (TTP). Thus, we studied the role of absolute lymphocyte count (ALC) prior to rituximab therapy on treatment efficacy and TTP in FL patients. Between 1996 and 2002, 79 FL patients were treated with single agent rituximab during their lymphoma treatment at the Mayo Clinic. The median age of the cohort was 56.6 years (range: 25-98 years). The median TTP was 12.5 months (range: 1-76 months). Superior TTP was observed with an ALC ≥0.89 × 109/l (n = 40) compared with an ALC <0.89 × 109/l (n = 39) at the time of rituximab therapy (median: 36.5 vs. 8.1 months, respectively, P < 0.0009). Higher complete response rates were observed in the ALC ≥0.89 × 109/l (23/40, 58%) compared with the ALC <0.89 × 109/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy.

Original languageEnglish (US)
Pages (from-to)409-415
Number of pages7
JournalBritish Journal of Haematology
Volume137
Issue number5
DOIs
StatePublished - Jun 2007

Fingerprint

Follicular Lymphoma
Lymphocyte Count
Therapeutics
Rituximab
Immune System
Lymphoma
Multivariate Analysis
Antibodies

Keywords

  • Absolute lymphocyte count
  • Follicular (grades 1 and 2) lymphomas
  • Follicular Lymphoma International Prognostic Index
  • Rituximab
  • Time to progression

ASJC Scopus subject areas

  • Hematology

Cite this

Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. / Behl, Deepti; Ristow, Kay; Markovic, Svetomir Nenad; Witzig, Thomas Elmer; Habermann, Thomas Matthew; Colgan, Joseph P.; Inwards, David J.; White, William L.; Ansell, Stephen Maxted; Micallef, Ivana; Johnston, Patrick Bruce; Porrata, Luis F.

In: British Journal of Haematology, Vol. 137, No. 5, 06.2007, p. 409-415.

Research output: Contribution to journalArticle

@article{1b75ea67b9904acf86e44c5a11259a19,
title = "Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas",
abstract = "The immunologic mechanisms of action of rituximab include complement mediated lysis and antibody-dependent cellular cytotoxicity. We hypothesised that a stronger host immune system prior to rituximab therapy for follicular (grades 1and 2) lymphomas (FL) would result in better response rates and longer time to progression (TTP). Thus, we studied the role of absolute lymphocyte count (ALC) prior to rituximab therapy on treatment efficacy and TTP in FL patients. Between 1996 and 2002, 79 FL patients were treated with single agent rituximab during their lymphoma treatment at the Mayo Clinic. The median age of the cohort was 56.6 years (range: 25-98 years). The median TTP was 12.5 months (range: 1-76 months). Superior TTP was observed with an ALC ≥0.89 × 109/l (n = 40) compared with an ALC <0.89 × 109/l (n = 39) at the time of rituximab therapy (median: 36.5 vs. 8.1 months, respectively, P < 0.0009). Higher complete response rates were observed in the ALC ≥0.89 × 109/l (23/40, 58{\%}) compared with the ALC <0.89 × 109/l (5/39, 13{\%}) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy.",
keywords = "Absolute lymphocyte count, Follicular (grades 1 and 2) lymphomas, Follicular Lymphoma International Prognostic Index, Rituximab, Time to progression",
author = "Deepti Behl and Kay Ristow and Markovic, {Svetomir Nenad} and Witzig, {Thomas Elmer} and Habermann, {Thomas Matthew} and Colgan, {Joseph P.} and Inwards, {David J.} and White, {William L.} and Ansell, {Stephen Maxted} and Ivana Micallef and Johnston, {Patrick Bruce} and Porrata, {Luis F.}",
year = "2007",
month = "6",
doi = "10.1111/j.1365-2141.2007.06596.x",
language = "English (US)",
volume = "137",
pages = "409--415",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas

AU - Behl, Deepti

AU - Ristow, Kay

AU - Markovic, Svetomir Nenad

AU - Witzig, Thomas Elmer

AU - Habermann, Thomas Matthew

AU - Colgan, Joseph P.

AU - Inwards, David J.

AU - White, William L.

AU - Ansell, Stephen Maxted

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Porrata, Luis F.

PY - 2007/6

Y1 - 2007/6

N2 - The immunologic mechanisms of action of rituximab include complement mediated lysis and antibody-dependent cellular cytotoxicity. We hypothesised that a stronger host immune system prior to rituximab therapy for follicular (grades 1and 2) lymphomas (FL) would result in better response rates and longer time to progression (TTP). Thus, we studied the role of absolute lymphocyte count (ALC) prior to rituximab therapy on treatment efficacy and TTP in FL patients. Between 1996 and 2002, 79 FL patients were treated with single agent rituximab during their lymphoma treatment at the Mayo Clinic. The median age of the cohort was 56.6 years (range: 25-98 years). The median TTP was 12.5 months (range: 1-76 months). Superior TTP was observed with an ALC ≥0.89 × 109/l (n = 40) compared with an ALC <0.89 × 109/l (n = 39) at the time of rituximab therapy (median: 36.5 vs. 8.1 months, respectively, P < 0.0009). Higher complete response rates were observed in the ALC ≥0.89 × 109/l (23/40, 58%) compared with the ALC <0.89 × 109/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy.

AB - The immunologic mechanisms of action of rituximab include complement mediated lysis and antibody-dependent cellular cytotoxicity. We hypothesised that a stronger host immune system prior to rituximab therapy for follicular (grades 1and 2) lymphomas (FL) would result in better response rates and longer time to progression (TTP). Thus, we studied the role of absolute lymphocyte count (ALC) prior to rituximab therapy on treatment efficacy and TTP in FL patients. Between 1996 and 2002, 79 FL patients were treated with single agent rituximab during their lymphoma treatment at the Mayo Clinic. The median age of the cohort was 56.6 years (range: 25-98 years). The median TTP was 12.5 months (range: 1-76 months). Superior TTP was observed with an ALC ≥0.89 × 109/l (n = 40) compared with an ALC <0.89 × 109/l (n = 39) at the time of rituximab therapy (median: 36.5 vs. 8.1 months, respectively, P < 0.0009). Higher complete response rates were observed in the ALC ≥0.89 × 109/l (23/40, 58%) compared with the ALC <0.89 × 109/l (5/39, 13%) (P < 0.0001). Multivariate analysis showed ALC to be an independent predictor for TTP. This study supports our hypothesis that a higher ALC predicts longer TTP following rituximab therapy.

KW - Absolute lymphocyte count

KW - Follicular (grades 1 and 2) lymphomas

KW - Follicular Lymphoma International Prognostic Index

KW - Rituximab

KW - Time to progression

UR - http://www.scopus.com/inward/record.url?scp=34247867850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247867850&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2007.06596.x

DO - 10.1111/j.1365-2141.2007.06596.x

M3 - Article

C2 - 17433025

AN - SCOPUS:34247867850

VL - 137

SP - 409

EP - 415

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -